Principal Investigator
Zeina Hannoush
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20221092
Clinical Trial Summary
An Open-Label Extension Study of the Safety of Relacorilant
(CORT125134) in the Treatment of the Signs and Symptoms
of Endogenous Cushing Syndrome
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Burlett Masters
Phone Number
+1 (305) 2435354
Email
bmasters2@miami.edu